You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

711 Results
The following information answers many of the questions primary care physicians commonly ask about the Screening Activity Report and the included...
Drug
Other Name(s): Sylvant®
Mar 2025
Regimen
Cancer Type:
Hematologic, 
Rare Diseases
Intent: Palliative
Funding:
New Drug Funding Program
    Siltuximab - Multicentric Castleman’s Disease (MCD)
Mar 2025
Drug
Other Name(s): Caelyx®
Mar 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Liposomal DOXOrubicin - Single Agent Treatment of Platinum Sensitive Ovarian Fallopian Tube or Primary Peritoneal Cancer
New Drug Funding Program
    Liposomal Doxorubicin - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer
Mar 2025
Regimen
Cancer Type:
Sarcoma, 
Kaposi's Sarcoma
Intent: Palliative
Funding:
New Drug Funding Program
    Liposomal Doxorubicin - HIV-positive Kaposi's Sarcoma
Mar 2025
Regimen
Intent: Palliative
Mar 2025
Les programmes cliniques d’Action Cancer Ontario sont mis en œuvre en collaboration avec les cliniciens des Programmes régionaux de cancérologie en...
Guidelines and Advice
Updated
Mar 2025
Les programmes provinciaux de remboursement des médicaments (PPRM) permettent de financer les médicaments contre le cancer et les services connexes....

Pages